Novavax’s COVID-19 vaccine has proven effective against COVID-19 but less so against the variant first found in South Africa. An early analysis found the vaccine was 90% effective, but that dropped to 50% in a South Africa trial. (The New York Times)

The Food and Drug Administration has delayed its decision on Biogen’s Alzheimer’s drug aducanumab. The delay signals the FDA hasn’t yet rejected the company’s application, despite criticism over the drug’s mixed trial data. (Endpoints News)

Challenges remain for health systems and public health officials across the U.S. tracking the administration of vaccine shots, with data discrepancies continuing to create issues. Accurate data collection will be essential in addressing vaccine distribution inequities. (STAT)

Johnson & Johnson’s COVID-19 vaccine was 66% successful in protecting against COVID-19. The company plans to ask the FDA in early February for emergency use authorization of its vaccine. (The Wall Street Journal)

Researchers are beginning to study the long-term effects of COVID-19 on brain health. The SARS CoV-2 Impact on Behavior and Cognitionproject will examine brain health outcomes among COVID-19 survivors across 40 countries. (Forbes)